Cardigan

Type Here to Get Search Results !

Russia Develops Enteromix: World’s First mRNA-Based Cancer Vaccine

Russia Develops Enteromix: World’s First mRNA-Based Cancer Vaccine

Russia has introduced Enteromix, the world’s first mRNA-based cancer vaccine, marking a significant breakthrough in cancer treatment. According to researchers, the vaccine has demonstrated remarkable effectiveness and safety in trials, offering new hope to millions of cancer patients worldwide.


Early Clinical Use and Approval Status
The vaccine has already been made available in select oncology centers under early clinical use and is now awaiting final approval from the Ministry of Health for a wider public rollout across Russia.

How Enteromix Works
Developed using the same mRNA technology used in COVID-19 vaccines, Enteromix is a next-generation therapy designed to train the immune system to identify and destroy cancer cells while leaving healthy cells unharmed. Unlike chemotherapy or radiation treatments, researchers report that no serious side effects were observed during clinical testing.

Research and Development
The vaccine was jointly developed by the National Medical Research Radiological Centre in partnership with the Engelhardt Institute of Molecular Biology (EIMB). It is administered through a simple intramuscular injection, making it easier and more accessible for patients.

Who Can Benefit from Enteromix
Experts suggest that the vaccine has the potential to help a wide range of patients, including those diagnosed with:
  • Lung cancer
  • Breast cancer
  • Colorectal cancer
  • Pancreatic cancer
  • Hereditary cancer syndromes such as BRCA1 and BRCA2
  • Chemotherapy-resistant tumors
  • Immunocompromised patients with limited treatment options
  • A New Era in Cancer Treatment
  • Medical experts believe Enteromix represents a major step forward in the fight against cancer, potentially transforming the way doctors approach treatment and significantly improving patient survival rates in the coming years.

Enjoyed this article? Share your feedback!